TABLE 1.
Summary of Groups Used for Analyses
| FACS | Pneumococcal | MMR | ||||
|---|---|---|---|---|---|---|
| HU = 91 | Placebo = 88 | HU = 74 | Placebo = 70 | HU = 67 | Placebo = 66 | |
| Boys | 45% | 42% | 45% | 47% | 43% | 47% |
| Study visit | ||||||
| Pretreatment (N) | 91 | 88 | 73 | 69 | — | — |
| Age, mo (SD) | 12.5 (2.6) | 12.8 (3.1) | 12.9 (2.6) | 13.1 (2.7) | — | — |
| 2–10 wk after MMR (N) | — | — | — | — | 40 | 38 |
| Age, mo (SD) | — | — | — | — | 14.7 (3.1) | 15.0 (1.9) |
| Days after vaccination [min, max] | — | — | — | — | 36 [11, 73] | 37 [12, 75] |
| 2–10 wk after MMR on treatmenta (N) | — | — | — | — | 15 | 25 |
| Age, mo (SD) | — | — | — | — | 15.7 (3.1) | 15.3 (2.0) |
| Days after vaccination [min, max] | — | — | — | — | 33 [13, 61] | 38 [14, 75] |
| Age 24 mo (N) | 74 | 72 | 65 | 59 | 62 | 60 |
| Age, mo (SD) | 24.1 (1.1) | 24.4 (1.5) | 24.0 (1.1) | 24.1 (1.1) | 24.0 (1.1) | 24.2 (1.3) |
| Age 26 mo (PPV-23) (N) | — | — | 63 | 56 | — | — |
| Age, mo (SD) | — | — | 26.4 (2.2) | 26.3 (2.6) | — | — |
| End of study (N) | 86 | 86 | 66 | 62 | 59 | 58 |
| Age, mo (SD) | 37.8 (2.8) | 37.5 (2.9) | 37.9 (2.9) | 37.9 (3.0) | 37.8 (2.7) | 37.4 (2.8) |
FACS, fluorescence-activated cell sorting; HU, hydroxyurea.
a
Includes only participants vaccinated after receiving first dose of study treatment.
— indicates not applicable to study design.